Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Pregnancy and Childbirth
Published in: BMC Pregnancy and Childbirth 1/2024

Open Access 01-12-2024 | Phenobarbital | Research

Comparison of the effect of phenobarbital & levetiracetam in the treatment of neonatal abstinence syndrome (NAS) as adjuvant treatment in neonates admitted to the neonatal intensive care unit: a randomized clinical trial

Authors: Zahra Jamali, Mohammad Hosein Molaei-Farsangi, Habibeh Ahmadipour, Bahareh Bahmanbijari, Fatemeh Sabzevari, Zahra Daei Parizi

Published in: BMC Pregnancy and Childbirth | Issue 1/2024

Login to get access

Abstract

Background

Infants who are born from mothers with substance use disorder might suffer from neonatal abstinence syndrome (NAS) and need treatment with medicines. One of these medicines is phenobarbital, which may cause side effects in long-term consumption. Alternative drugs can be used to reduce these side effects. This study seeks the comparison of the effects of phenobarbital & levetiracetam as adjuvant therapy in neonatal abstinence syndrome.

Methods

This randomized clinical trial was performed in one year from May 2021 until May 2022. The neonates who were born from mothers with substance use disorder and had neonatal abstinence syndrome in Afzalipoor Hospital of Kerman were studied. The treatment started with morphine initially and every four hours the infants were checked. The infants who were diagnosed with uncontrolled symptoms After obtaining informed consent from the parents were randomly divided into two groups and treated with secondary drugs, either phenobarbital or levetiracetam.

Results

Based on the obtained results, it was clear that there was no significant difference between the hospitalization time of the two infant groups under therapy (phenobarbital: 18.59 days versus Levetiracetam 18.24 days) (P-value = 0.512). Also, there was no significant difference between both groups in terms of the frequency of re-hospitalization during the first week after discharge, the occurrence of complications, and third treatment line prescription (P-value = 0.644).

Conclusions

Based on the obtained results, like hospitalization duration time (P-value = 0.512) it seems that levetiracetam can be used to substitute phenobarbital in treating neonatal abstinence syndrome.

Trial registration

The current study has been registered in the Iran registry of clinical trials website (fa.irct.ir) on the date 25/2/2022 with registration no. IRCT20211218053444N2.
Appendix
Available only for authorised users
Literature
1.
Griffiths SK, Campbell JP. Placental structure, function and drug transfer. Continuing Educ Anaesth Crit Care Pain. 2015;15(2):84–9.CrossRef
2.
Mashmool A, Bakhshani N. Prevalence of drug withdrawal symptoms in infants and comparison symptoms according to mothers job and infants birth order in Zahedan. J Res Behav Sci. 2015;13(1):22–8. [In Persian].
3.
Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000–2009. JAMA. 2012;307(18):1934–40.CrossRefPubMed
4.
Bio LL, Siu A, Poon CY. Update on the pharmacologic management of neonatal abstinence syndrome. J Perinatology: Official J Calif Perinat Association. 2011;31(11):692–701.CrossRef
5.
6.
Hudak M, Tan R. Committee on drugs; committee on fetus and newborn; American academy of pediatrics. Neonatal drug Withdrawal Pediatr. 2012;129(2):e540–60.
7.
Coyle MG, Ferguson A, Lagasse L, Oh W, Lester B. Diluted tincture of opium (dto) and phenobarbital versus dto alone for neonatal opiate withdrawal in term infants. J Pediatr. 2002;140(5):561–4.CrossRefPubMed
8.
Agthe AG, Kim GR, Mathias KB, et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics. 2009;123(5):e849–56.CrossRefPubMed
9.
Chen J, Cai F, Cao J, Zhang X, Li S. Long-term antiepileptic drug administration during early life inhibits hippocampal neurogenesis in the developing brain. J Neurosci Res. 2009;87(13):2898–907.CrossRefPubMed
10.
Meador KJ, Baker G, Cohen MJ, Gaily E, Westerveld M. Cognitive/behavioral teratogenetic effects of antiepileptic drugs. Epilepsy & behavior: E&B. 2007;11(3):292–302.
11.
Bhardwaj SK, Forcelli PA, Palchik G, Gale K, Srivastava LK, Kondratyev A. Neonatal exposure to phenobarbital potentiates schizophrenia-like behavioral outcomes in the rat. Neuropharmacology. 2012;62(7):2337–45.CrossRefPubMed
12.
Sulzbacher S, Farwell JR, Temkin N, Lu AS, Hirtz DG. Late cognitive effects of early treatment with phenobarbital. Clin Pediatr. 1999;38(7):387–94.CrossRef
13.
Deborah G, Ta Chuan C, Karin B et al. Does henobarbital used for febrile seizures cause sleep disturbances? Pediatr Neurol. 1993;94–100.
14.
Vining EP, Mellitis ED, Dorsen MM, et al. Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics. 1987;80(2):165–74.CrossRefPubMed
15.
Swaiman KF, Ashwal S, Ferriero DM, et al. Swaiman’s pediatric neurology: principles and practice. 6th ed. Amsterdam: Elsevier Health Sciences; 2017.
16.
Surran B, Visintainer P, Chamberlain S, Kopcza K, Shah B, Singh R. Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. J Perinatology: Official J Calif Perinat Association. 2013;33(12):954–9.CrossRef
17.
Martin RJ, Fanaroff AA, Walsh MC. Fanaroff and martin’s neonatal-perinatal medicine e-book: Diseases of the fetus and infant. Elsevier Health Sciences; 2020.
18.
Lissauer T, Fanaroff AA, Miall L, Fanaroff J. Neonatology at a glance. New York: Wiley; 2020.
19.
Sharpe C, Reiner GE, Davis SL et al. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics. 2020;145(6).
20.
Thibault C, Naim MY, Abend NS, et al. A retrospective comparison of phenobarbital and levetiracetam for the treatment of seizures following cardiac surgery in neonates. Epilepsia. 2020;61(4):627–35.CrossRefPubMed
21.
Gowda VK, Romana A, Shivanna NH, Benakappa N, Benakappa A. Levetiracetam versus phenobarbitone in neonatal seizures - a randomized controlled trial. Indian Pediatr. 2019;56(8):643–6.CrossRefPubMed
22.
El-Dib M, Soul JS. The use of phenobarbital and other anti-seizure drugs in newborns. Semin Fetal Neonatal Med. 2017;22(5):321–7.CrossRefPubMed
23.
Soul JS, Bergin AM, Stopp C, et al. A pilot randomized, controlled, double-blind trial of bumetanide to treat neonatal seizures. Ann Neurol. 2021;89(2):327–40.CrossRefPubMed
24.
Qiao MY, Cui HT, Zhao LZ, Miao JK, Chen QX. Efficacy and safety of levetiracetam vs. Phenobarbital for neonatal seizures: a systematic review and meta-analysis. Front Neurol. 2021;12:747745.CrossRefPubMedPubMedCentral
25.
Merhar SL, Ounpraseuth S, Devlin LA et al. Phenobarbital and clonidine as secondary medications for neonatal opioid withdrawal syndrome. Pediatrics. 2021;147(3).
26.
Brusseau C, Burnette T, Heidel RE. Clonidine versus Phenobarbital as adjunctive therapy for neonatal abstinence syndrome. J Perinatology: Official J Calif Perinat Association. 2020;40(7):1050–5.CrossRef
27.
Nayeri F, Sheikh M, Kalani M, et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatr. 2015;15:57.CrossRefPubMedPubMedCentral
28.
Zimmermann U, Christoph R, Angelo D, et al. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. Eur J Pediatrics. 2020;179:141–9.CrossRef
Metadata
Title
Comparison of the effect of phenobarbital & levetiracetam in the treatment of neonatal abstinence syndrome (NAS) as adjuvant treatment in neonates admitted to the neonatal intensive care unit: a randomized clinical trial
Authors
Zahra Jamali
Mohammad Hosein Molaei-Farsangi
Habibeh Ahmadipour
Bahareh Bahmanbijari
Fatemeh Sabzevari
Zahra Daei Parizi
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Pregnancy and Childbirth / Issue 1/2024
Electronic ISSN: 1471-2393
DOI
https://doi.org/10.1186/s12884-024-06433-y

Other articles of this Issue 1/2024

BMC Pregnancy and Childbirth 1/2024 Go to the issue

Research

Care and services partnership in Quebec birthing centres: myth or reality?

Research

What factors influence couples’ decisions to have children? Evidence from a systematic scoping review

Research

Pregnancy and lactation-associated osteoporosis as a major type of premenopausal osteoporosis: a retrospective cohort study based on real-world data

Research

Factors associated with anaemia among pregnant women in Rwanda: an analysis of the Rwanda demographic and health survey of 2020

Research

Role of mitochondrial DNA level in epidural-related maternal fever: a single-centre, observational, pilot study

Research

Assessment of relevance and actual implementation of person-centeredness in healthcare and social support services for women with unintended pregnancy in Germany (CarePreg): results of expert workshops